港股异动 | 康宁杰瑞制药-B(09966)再涨超7% 本月底将发中期业绩预计上半年利润不少于2000万元

智通财经2025-08-18

智通财经APP获悉，康宁杰瑞制药-B(09966)再涨超7%，截至发稿，涨6.56%，报9.59港元，成交额3218.92万港元。消息面上，康宁杰瑞制药将于8月28日召开董事会会议以审批中期业绩。公司此前预计，上半年取得利润不少于人民币2000万元，去年同期亏损约人民币4490万元。公司于报告期内转亏为盈，主要基于三项授权合作的里程碑收入和商业化产品的销售收入。此外，康宁杰瑞制药近日公告，公司自主...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2560946974?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-18 14:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560946974","market":"fut","top_or_hot":-1,"title":"港股异动 | 康宁杰瑞制药-B(09966)再涨超7% 本月底将发中期业绩 预计上半年利润不少于2000万元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，康宁杰瑞制药-B(09966)再涨超7%，截至发稿，涨6.56%，报9.59港元，成交额3218.92万港元。消息面上，康宁杰瑞制药将于8月28日召开董事会会议以审批中期业绩。公司此前预计，上半年取得利润不少于人民币2000万元，去年同期亏损约人民币4490万元。公司于报告期内转亏为盈，主要基于三项授权合作的里程碑收入和商业化产品的销售收入。此外，康宁杰瑞制药近日公告，公司自主...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1330808.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康宁杰瑞制药-B(09966)再涨超7% 本月底将发中期业绩 预计上半年利润不少于2000万元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康宁杰瑞制药-B(09966)再涨超7% 本月底将发中期业绩 预计上半年利润不少于2000万元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-18 14:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1330808.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，康宁杰瑞制药-B(09966)再涨超7%，截至发稿，涨6.56%，报9.59港元，成交额3218.92万港元。消息面上，康宁杰瑞制药将于8月28日召开董事会会议以审批中期业绩。公司此前预计，上半年取得利润不少于人民币2000万元，去年同期亏损约人民币4490万元。公司于报告期内转亏为盈，主要基于三项授权合作的里程碑收入和商业化产品的销售收入。此外，康宁杰瑞制药近日公告，公司自主...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1330808.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1330808.html","article_id":"2560946974","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560946974","pubTimestamp":1755499845,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，康宁杰瑞制药-B再涨超7%，截至发稿，涨6.56%，报9.59港元，成交额3218.92万港元。消息面上，康宁杰瑞制药将于8月28日召开董事会会议以审批中期业绩。公司此前预计，上半年取得利润不少于人民币2000万元，去年同期亏损约人民币4490万元。公司计划开展用于治疗晚期恶性实体瘤的JSKN022首次人体临床研究。目前全球范围内尚无靶向整合素αvβ6或PD-L1的ADC上市，相关在研药物均处于临床研究阶段。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","09966":"康宁杰瑞制药-B"},"translate_title":"Changes in Hong Kong stocks | Corning Jereh Pharmaceuticals-B (09966) rose more than 7% again and will issue interim results at the end of this month. It is expected that the profit in the first half of the year will be no less than 20 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":1},"content_text":"智通财经APP获悉，康宁杰瑞制药-B(09966)再涨超7%，截至发稿，涨6.56%，报9.59港元，成交额3218.92万港元。消息面上，康宁杰瑞制药将于8月28日召开董事会会议以审批中期业绩。公司此前预计，上半年取得利润不少于人民币2000万元，去年同期亏损约人民币4490万元。公司于报告期内转亏为盈，主要基于三项授权合作的里程碑收入和商业化产品的销售收入。此外，康宁杰瑞制药近日公告，公司自主研发的程序性死亡配体1（PD-L1）/整合素αvβ6双特异性抗体偶联药物（ADC）JSKN022的新药临床试验申请已获中国国家药品监督管理局药品审评中心正式受理。公司计划开展用于治疗晚期恶性实体瘤的JSKN022首次人体临床研究。目前全球范围内尚无靶向整合素αvβ6或PD-L1的ADC上市，相关在研药物均处于临床研究阶段。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2560946974","isCrawlerRequest":true}

港股异动 | 康宁杰瑞制药-B(09966)再涨超7% 本月底将发中期业绩 预计上半年利润不少于2000万元

精彩评论

港股异动 | 康宁杰瑞制药-B(09966)再涨超7% 本月底将发中期业绩预计上半年利润不少于2000万元